Intra-cerebral ventricular infusion of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer in the treatment of a rat glioma

Int J Radiat Oncol Biol Phys. 1990 Jul;19(1):85-7. doi: 10.1016/0360-3016(90)90138-a.

Abstract

The efficacy of 5-iodo-2-deoxyuridine (IUDR) as a radiosensitizer when administered by continuous infusion into the cerebral spinal fluid (CSF) of the lateral cerebral ventricle was evaluated in a 9L gliosarcoma rat brain tumor model. Stereotactic implantation of a 5 x 10(4) tumor cell suspension into the left caudate nucleus was carried out in four groups of 10 rats each. Control animals had a median survival of 16.9 days (range 16-21 days). IUDR, 8.4 mg over 7 days administered by continuous infusion into the left lateral ventricle produced a slight survival advantage (median survival 21.5 days, range 12-56). Irradiation of the entire brain, 8 Gy on days 4, 6 and 7 after tumor cell implantation also produced a slight improvement in survival (median 19.5 days, range 17-34). The combination of radiation and IUDR infusion into the CSF produced a marked survival advantage (median 30.5, range 22-54) compared to the control and single modality treatment groups. This is the first demonstration of the effectiveness of IUDR as a radiosensitizer when administered into the lateral cerebral ventricle in the treatment of an intraparenchymal brain tumor.

MeSH terms

  • Animals
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / radiotherapy
  • Death
  • Glioma / drug therapy*
  • Glioma / radiotherapy
  • Idoxuridine / administration & dosage*
  • Idoxuridine / therapeutic use
  • Injections, Intraventricular
  • Male
  • Neoplasm Transplantation
  • Radiation-Sensitizing Agents / administration & dosage*
  • Radiation-Sensitizing Agents / therapeutic use
  • Rats
  • Rats, Inbred F344

Substances

  • Radiation-Sensitizing Agents
  • Idoxuridine